Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ESRRA | P11474 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10620277 | 0.88 | TDP1 (0.61) | MAPTALDH1A1MTNR1AMTNR1BTDP1 | |
| Hydrochloric Acid SCHEMBL11326749 | 0.87 | TDP1 (0.59) | MAPTALDH1A1MTNR1AMTNR1BTDP1 | |
| SCHEMBL18281388 | 0.82 | CYP11B1 (0.55) | MAPTALDH1A1MTNR1AMTNR1BESRRA | |
| SCHEMBL14384694 | 0.82 | TTR (0.60) | MAPTALDH1A1MTNR1AMTNR1BESRRA | |
| SCHEMBL3728925 | 0.82 | ALDH1A1 (0.56) | MAPTALDH1A1MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL11325646 | 0.81 | MAPT (0.55) | MAPTALDH1A1MTNR1AMTNR1BESRRA | |
| SCHEMBL8590172 | 0.80 | TDP1 (0.54) | MAPTALDH1A1TDP1HSD17B10KDM4E | |
| SCHEMBL9655279 | 0.80 | TTR (0.53) | MAPTALDH1A1HPGDIKBKBRAB9A | |
| SCHEMBL853330 | 0.80 | ALDH1A1 (0.56) | MAPTALDH1A1TDP1LMNAHSD17B10 | |
| SCHEMBL29594166 | 0.80 | ALDH1A1 (0.56) | MAPTALDH1A1TDP1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1692085-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | Chiron Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | MAPT 782/4885ALDH1A1 3296/4885MTNR1A 3752/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | MAPT 160/4885ALDH1A1 3003/4885MTNR1A 234/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | MAPT 575/4885ALDH1A1 276/4885MTNR1A 1380/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | MAPT 57/4885ALDH1A1 1196/4885MTNR1A 2690/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | MAPT 711/4885ALDH1A1 152/4885MTNR1A 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.